SEC Tracker
Get the app

Structure Therapeutics GPCR

Structure Therapeutics reports Q3 2026 financial results

Structure Therapeutics (GPCR) filed an 8-K with the SEC on Nov 9, 2026, 4:12 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Cash, cash equivalents and short-term investments of $1.2 billion as of September 30, 2026
  2. Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 trials of aleniglipron enrolling, with topline data expected in 2H 2028
  3. ACCG-2671 Phase 1/2a trial shows 6-day half-life with no serious adverse events

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Structure Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.